Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment for hematological malignancies and nonmalignant diseases. Furthermore, haploidentical stem cell transplantation has been developed in the past two decades as another potential strategy for patients with no HLA-matched donor.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Qiao-Zhu Zeng, Yuan-Yuan Zhang, Ye-Jun Wu, Zhuang-Yi Zhang, Jia-Ning Zhang, Hai-Xia Fu, Jing-Zhi Wang, Feng-Rong Wang, Chen-Hua Yan, Xiao-Dong Mo, Yu Wang, Yu-Hong Chen, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang Source Type: research
More News: Biology | Cancer & Oncology | Hematology | Stem Cell Therapy | Stem Cells | Transplants | Tuberculosis